| |
| | Addition Of A Bile Acid Sequestrant (WelChol, Colesevelam HCl) To Statin Therapy Significantly Reduces Median Hs-CRP ... |
 | | This is the first data to demonstrate that WelChol, a bile acid sequestrant (BAS), when added to statin therapy, reduces hs-CRP levels, which is a marker for inflammation and also a strong predictor of coronary heart disease (CHD) events(1, 2). |
 | | "Bile acid sequestrants were one of the first approved cholesterol- lowering drugs, having been studied in the 1970s, before hs-CRP was routinely measured," said lead study investigator Harold E. Bays, MD, FACP, Louisville Metabolic and Atherosclerosis Research Center Inc., Louisville, KY. |
 | | Because WelChol is engineered for affinity, specificity and high capacity bile acid binding, it may have a lower potential for drug-drug interaction. |
| www.medicalnewstoday.com /medicalnews.php?newsid=41805 (1458 words) |
|